Group 1 - The core viewpoint of the article is that Changfeng Pharmaceutical (2652.HK) is launching an IPO, offering 41.198 million H-shares at a price of HKD 14.75 per share, aiming to raise up to HKD 608 million [1] - The public offering accounts for 10% of the total shares, with the remaining shares allocated for international placement [1] - The expected listing date for the shares is October 8 [1] Group 2 - The company plans to allocate approximately 40% of the net proceeds for the ongoing research and clinical development of existing inhalation product candidates [1] - About 20% of the funds will be used for preclinical research of various other pipeline projects and technologies [1] - Approximately 30% will be directed towards the expansion and upgrading of production facilities, equipment procurement, and production management systems [1] - The remaining 10% will be used for working capital and other general corporate purposes [1]
长风药业(2652.HK)今起招股 入场费7449港元
Xin Lang Cai Jing·2025-09-26 01:01